Preliminary Study of 11C-Choline PET/CT for T Staging of Locally Advanced Nasopharyngeal Carcinoma: Comparison with 18F-FDG PET/CT

Hubing Wu, Quanshi Wang, Ming-Fang Wang, Zhen Xiaokang, Wenlan Zhou, Hongsheng LiJournal of Nuclear Medicine 2011 · DOI

TL;DR

This study investigates whether <sup>11</sup>C-choline PET/CT can improve the accuracy of T staging for locally advanced nasopharyngeal carcinoma (NPC) compared to the standard <sup>18</sup>F-FDG PET/CT. The findings suggest that <sup>11</sup>C-choline PET/CT offers better delineation of tumor invasion, particularly in critical areas like the skull base and intracranial regions, potentially leading to more precise treatment planning.

What Problem Does This Paper Address?

Nasopharyngeal carcinoma (NPC) is a challenging cancer, especially when locally advanced, often involving nearby critical structures like the skull base and intracranial areas. Accurate T staging (determining the extent of the primary tumor) is crucial for effective radiation therapy planning. While <sup>18</sup>F-FDG PET/CT is a valuable tool for detecting NPC and its metastases, it has limitations in T staging due to the high physiological uptake of <sup>18</sup>F-FDG in the brain. This can obscure tumors located near or within the brain, leading to underestimation of tumor extent. The researchers aimed to explore if <sup>11</sup>C-choline, a PET tracer with lower uptake in normal brain tissue, could overcome these limitations and improve the accuracy of T staging for locally advanced NPC.

Methods

The study employed a comparative approach, performing both <sup>18</sup>F-FDG PET/CT and <sup>11</sup>C-choline PET/CT on 15 patients diagnosed with newly diagnosed or recurrent locally advanced NPC. Both imaging modalities were analyzed by experienced nuclear medicine physicians unaware of other imaging results. The analysis involved both qualitative visual evaluation of tumor delineation and quantitative assessment using maximum standardized uptake value (SUVmax) and tumor-to-brain (T/B) ratios. The researchers specifically looked for improvements in delineating intracranial, skull base, and orbital invasion.

Datasets

The study utilized data from 15 patients with locally advanced nasopharyngeal carcinoma. These patients underwent both <sup>18</sup>F-FDG PET/CT and <sup>11</sup>C-choline PET/CT scans. The clinical data, including diagnosis, pathology, and lesion invasion confirmed by MRI or CT, were compiled and analyzed. No new datasets were introduced; the study relied on patient data collected for the research.

Key Insights and Ideas

  • <sup>11</sup>C-Choline's Advantage in Brain-Adjacent Regions: The core insight is that <sup>11</sup>C-choline's lower background uptake in normal brain tissue significantly enhances its ability to delineate tumors near or within the brain compared to <sup>18</sup>F-FDG. This is a critical advantage for NPC, where such invasions are common.
  • Improved Tumor-to-Brain Ratio: The significantly higher T/B ratio observed with <sup>11</sup>C-choline directly translates to better contrast between tumor and normal tissue, making subtle invasions more apparent.
  • Potential for More Precise Treatment Planning: By offering clearer visualization of tumor extent, <sup>11</sup>C-choline PET/CT could lead to more accurate gross tumor volume (GTV) determination, which is fundamental for optimizing radiation therapy and potentially improving patient outcomes.

Key Results

  • Sensitivity: <sup>11</sup>C-choline PET/CT demonstrated 100% sensitivity in detecting locally advanced NPC, compared to 86.6% for <sup>18</sup>F-FDG PET/CT.
  • Quantitative Differences: While <sup>18</sup>F-FDG showed higher SUVmax values (indicating greater tracer uptake in lesions), <sup>11</sup>C-choline yielded a substantially higher T/B ratio (18.62 ± 7.95 vs. 1.38 ± 0.59), highlighting its superior contrast.
  • Qualitative Improvements: <sup>11</sup>C-choline PET/CT improved the delineation of intracranial invasion in 6 of 12 patients, skull base invasion in 4 of 14 patients, and orbital invasion in 3 of 3 patients. This visual improvement was statistically significant for intracranial invasion.
  • Discordant Findings: In cases where <sup>18</sup>F-FDG PET/CT was negative or indeterminate for certain invasions (e.g., insidious skull base involvement, orbital invasion due to ocular muscle uptake), <sup>11</sup>C-choline PET/CT often provided positive and clearer visualization.

Limitations and Future Work

The authors acknowledge that their study was limited by a relatively small and heterogeneous patient population. They suggest that future randomized, controlled studies with larger patient cohorts are needed to confirm their findings. Additionally, while <sup>11</sup>C-choline showed promise, its uptake in certain normal brain structures like the choroid plexus was noted, though it did not significantly impact T staging in this study. Future research should also focus on determining the comparative accuracy of <sup>11C</sup>-choline PET/CT against MRI for tumor delineation and exploring its potential complementary role with MRI.

Summary updated

Abstract

(11)C-choline can improve the quality of PET/CT in the T staging of NPC.
BibTeX
@article{wu2011preliminary,
  author = {Hubing Wu and Quanshi Wang and Ming-Fang Wang and Zhen Xiaokang and Wenlan Zhou and Hongsheng Li},
  title = {{Preliminary Study of <sup>11</sup>C-Choline PET/CT for T Staging of Locally Advanced Nasopharyngeal Carcinoma: Comparison with <sup>18</sup>F-FDG PET/CT}},
  journal = {Journal of Nuclear Medicine},
  year = {2011},
  doi = {10.2967/jnumed.110.081190},
}
Figure